| Autor: |
Verrijk, Ruud, Vleeming, Wim, Van Rooij, Hans H., Wemer, Johan, Porsius, Arijan J. |
| Zdroj: |
Journal of Pharmaceutical Sciences; March 1990, Vol. 79 Issue: 3 p236-239, 4p |
| Abstrakt: |
Milrinone (1, 6-dihydro-2-methyl-6-oxo[3, 4′-bipyridine]-5-carbonitrile) is a cardiotonic drug, currently under clinical investigation for the treatment of congestive heart failure.Its positive inotropic properties and its strong vasodilative action contribute to a favorable therapeutic effect. Plasma elimination of milrinone is generally by renal excretion of the unchanged drug. Since hemodynamic effects might influence the pharmacokinetics of renally eliminated drugs, we have investigated the plasma elimination of milrinone after different iv bolus doses of the compound in healthy rats. Half-times were 20.6 ± 5.5 min (0.3 mg/kg milrinone), 17.0 ± 1.8 min (1.0 mg/kg), 31.4 ± 4.5 min (3.0 mg/kg), and 95.5 ± 18.4 min (10.0 mg/kg). Clearances of milrinone showed a positive correlation with doses. Hemodynamic effects were dose dependent and (plasma) concentration dependent, and the maximum decrease in diastolic blood pressure was 54.5 ± 0.5 mmHg. The half-effective plasma concentration of milrinone was 1.0 ± 0.2 μM. The maximum increase in heart rate was 15%. We conclude that milrinone plasma elimination in rats is dose dependent, probably resulting from its strong vasodilator properties. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Plný text